Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v13050747 http://scihub22266oqcxt.onion/10.3390/v13050747 33923271!8146438!33923271     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2021 ; 13 (5): ä Nephropedia Template TP {{tp|p=33923271|t=2021. A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection |pdf=|usr=}}{{33923271}} gab.com Text A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33923271 #FOAvip As of April 2021, the COVID-19 pandemic has swept through 213 countries and infected more than 132 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programmes, whilst promising, remain in their infancy. A key to restricting the pandemic is the ability to minimize human-human transmission and to predict the infection status of the population in the face of emerging SARS-CoV-2 variants. Success in this area is dependent on the rapid detection of COVID-19 positive individuals with current/previous SARS-CoV-2 infection status. In this regard, the ability to detect antibodies directed against the SARS-CoV-Spike protein in patient sera represents a powerful biomarker for confirmation of infection. Here, we report the design of a proof-of-concept cell-based fluorescent serology assay (termed C19-S-I-IFA) to detect SARS-CoV-2 infection. The assay is based on the capture of IgG antibodies in the serum of COVID-19-positive patients using cells exogenously expressing SARS-CoV-2-Spike and their subsequent fluorescent detection. We validate the assay in 30 blood samples collected in Oxford, UK, in 2020 during the height of the pandemic. Importantly, the assay can be modified to express emerging Spike-variants to permit assessments of the cross-reactivity of patient sera to emerging SARS-CoV-2 strains. Twit Text FOAVip A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33923271 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33923271 #FOAvip English Wikipedia <ref>{{Cite pmid|33923271}}</ref> A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection #MMPMID33923271 Nguyen D; Skelly D; Goonawardane N Viruses 2021[Apr]; 13 (5): ä PMID33923271show ga As of April 2021, the COVID-19 pandemic has swept through 213 countries and infected more than 132 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programmes, whilst promising, remain in their infancy. A key to restricting the pandemic is the ability to minimize human-human transmission and to predict the infection status of the population in the face of emerging SARS-CoV-2 variants. Success in this area is dependent on the rapid detection of COVID-19 positive individuals with current/previous SARS-CoV-2 infection status. In this regard, the ability to detect antibodies directed against the SARS-CoV-Spike protein in patient sera represents a powerful biomarker for confirmation of infection. Here, we report the design of a proof-of-concept cell-based fluorescent serology assay (termed C19-S-I-IFA) to detect SARS-CoV-2 infection. The assay is based on the capture of IgG antibodies in the serum of COVID-19-positive patients using cells exogenously expressing SARS-CoV-2-Spike and their subsequent fluorescent detection. We validate the assay in 30 blood samples collected in Oxford, UK, in 2020 during the height of the pandemic. Importantly, the assay can be modified to express emerging Spike-variants to permit assessments of the cross-reactivity of patient sera to emerging SARS-CoV-2 strains. |A549 Cells[MESH] |Antibodies, Viral/blood[MESH] |COVID-19 Testing/*methods[MESH] |COVID-19/blood/diagnosis/immunology/*virology[MESH] |Cross Reactions[MESH] |Fluorescent Antibody Technique/*methods[MESH] |Humans[MESH] |Immunoglobulin G/blood[MESH] |Pandemics[MESH] |SARS-CoV-2/genetics/immunology/*isolation & purification[MESH] |Sensitivity and Specificity[MESH]A Novel Immunofluorescence Assay for the Rapid Serological Detection o(epmc).pdf DeepDyve Pubget Overpricing